|
1
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
van den Bent MJ, Geurts M, French PJ,
Smits M, Capper D, Bromberg JEC and Chang SM: Primary brain tumours
in adults. Lancet. 402:1564–1579. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tan AC, Ashley DM, López GY, Malinzak M,
Friedman HS and Khasraw M: Management of glioblastoma: State of the
art and future directions. CA Cancer J Clin. 70:299–312.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Qazi MA, Vora P, Venugopal C, Sidhu SS,
Moffat J, Swanton C and Singh SK: Intratumoral heterogeneity:
Pathways to treatment resistance and relapse in human glioblastoma.
Ann Oncol. 28:1448–1456. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Weller M, Wen PY, Chang SM, Dirven L, Lim
M, Monje M and Reifenberger G: Glioma. Nat Rev Dis Primers.
10(33)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Neftel C, Laffy J, Filbin MG, Hara T,
Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM,
et al: An integrative model of cellular states, plasticity, and
genetics for glioblastoma. Cell. 178(849.e21)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
McMahon JT, Studer M, Ulrich B, Revuelta
Barbero JM, Pradilla I, Palacios-Ariza MA and Pradilla G:
Circulating tumor DNA in adults with glioma: A systematic review
and Meta-analysis of biomarker performance. Neurosurgery.
91:231–238. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Horbinski C, Solomon DA, Lukas RV, Packer
RJ, Brastianos P, Wen PY, Snuderl M, Berger MS, Chang S, Fouladi M,
et al: Molecular testing for the world health organization
classification of central nervous system tumors: A review. JAMA
Oncol. 11:317–328. 2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wen PY and Packer RJ: The 2021 WHO
classification of tumors of the central nervous system: Clinical
implications. Neuro Oncol. 23:1215–1217. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Barault L, Amatu A, Bleeker FE, Moutinho
C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M,
Cassoni P, et al: Digital PCR quantification of MGMT methylation
refines prediction of clinical benefit from alkylating agents in
glioblastoma and metastatic colorectal cancer. Ann Oncol.
26:1994–1999. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Reardon DA and Cahill DP: A new era for
glioma therapy-targeting mutant IDH. Nat Rev Clin Oncol.
20:737–738. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mellinghoff IK, van den Bent MJ,
Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S,
Welsh L, Mason WP, et al: Vorasidenib in IDH1- or IDH2-mutant
low-grade glioma. N Engl J Med. 389:589–601. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mukherjee I, Park J, Patel AP and Baliga
NS: Transcriptional mechanisms of phenotypic plasticity in
glioblastoma. J Clin Oncol. 42 (16_suppl)(e14027)2024.
|
|
16
|
LeBlanc VG, Trinh DL, Aslanpour S, Hughes
M, Livingstone D, Jin D, Ahn BY, Blough MD, Cairncross JG, Chan JA,
et al: Single-cell landscapes of primary glioblastomas and matched
explants and cell lines show variable retention of inter- and
intratumor heterogeneity. Cancer Cell. 40:79–392.e9.
2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Migliozzi S, Adabbo B, Garofano L, Wu F,
Davila P, Komotar RJ, Ivan ME, Shah AH, Currall BB, Williams S, et
al: Restraint of cancer cell plasticity by spatial homotypic
clustering. Cancer Cell. 43:2206–2223.e10. 2025.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hamed AA, Hua K, Trinh QM, Simons BD,
Marioni JC, Stein LD and Dirks PB: Gliomagenesis mimics an injury
response orchestrated by neural crest-like cells. Nature.
638:499–509. 2025.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Stummer W, Pichlmeier U, Meinel T,
Wiestler OD, Zanella F and Reulen HJ: ALA-Glioma Study Group.
Fluorescence-guided surgery with 5-aminolevulinic acid for
resection of malignant glioma: A randomised controlled multicentre
phase III trial. Lancet Oncol. 7:392–401. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Moiyadi A, Syed P and Srivastava S:
Fluorescence-guided surgery of malignant gliomas based on
5-aminolevulinic acid: Paradigm shifts but not a panacea. Nat Rev
Cancer. 14(146)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
McCracken DJ, Schupper AJ, Lakomkin N,
Malcolm J, Painton Bray D and Hadjipanayis CG: Turning on the light
for brain tumor surgery: A 5-aminolevulinic acid story. Neuro
Oncol. 24 (Suppl 6):S52–S61. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Coty-Fattal Z, Smith H, McCord M,
Mejia-Bautista M, Dittman D, Primdahl D, Conway K, Becker N,
Ahrendsen JT, Santana-Santos L, et al: Rapid assessment of MGMT
promoter methylation status by droplet digital polymerase chain
reaction on intraoperative smear preparation: A proof-of-concept
study. J Neuropathol Exp Neurol. 85:280–284. 2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Singh S, Dey D, Barik D, Mohapatra I, Kim
S, Sharma M, Prasad S, Wang P, Singh A and Singh G: Glioblastoma at
the crossroads: Current understanding and future therapeutic
horizons. Signal Transduct Target Ther. 10(213)2025.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Arienti C, Pignatta S, Zanoni M, Zamagni
A, Cortesi M, Sarnelli A, Romeo A, Arpa D, Longobardi P, Bartolini
D, et al: High-pressure oxygen rewires glucose metabolism of
patient-derived glioblastoma cells and fuels inflammasome response.
Cancer Lett. 506:152–166. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Reardon DA, Brandes AA, Omuro A,
Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr
O, et al: Effect of Nivolumab vs bevacizumab in patients with
recurrent glioblastoma: The CheckMate 143 phase 3 randomized
clinical trial. JAMA Oncol. 6:1003–1010. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Schalper KA, Rodriguez-Ruiz ME, Diez-Valle
R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea
C, López-Diaz de Cerio A, Tejada S, et al: Neoadjuvant nivolumab
modifies the tumor immune microenvironment in resectable
glioblastoma. Nat Med. 25:470–476. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhao J, Chen AX, Gartrell RD, Silverman
AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A,
et al: Immune and genomic correlates of response to anti-PD-1
immunotherapy in glioblastoma. Nat Med. 25:462–469. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kreatsoulas D, Bolyard C, Wu BX, Cam H,
Giglio P and Li Z: Translational landscape of glioblastoma
immunotherapy for physicians: Guiding clinical practice with basic
scientific evidence. J Hematol Oncol. 15(80)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang Y, Chi X, Feng R, Xian N, Huang N,
Sun S, Zhao X, Zhang P, Liu K, Ma Y, et al: Intracranial delivery
of B7-H3-targeting CAR-T cells for recurrent glioblastoma: A phase
1 trial. Nat Med. 32:3268–3275. 2026.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Clubb JD, Shih RM, Gao TA, Shafer A,
Vajragiri S, Lam K, Talluri S, Bouren A, Brown CE, Ruivo P, et al:
Armored chimeric antigen receptor T-cell therapy targets
antigen-heterogeneous glioma. Cancer Res. 86:3781–3800.
2026.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kong S, Sengupta S, Tyler B, Bais AJ, Ma
Q, Doucette S, Zhou J, Sahin A, Carter BS, Brem H, et al:
Suppression of human glioma xenografts with second-generation
IL13R-specific chimeric antigen receptor-modified T cells. Clin
Cancer Res. 18:5949–5960. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mitchell DA, Batich KA, Gunn MD, Huang MN,
Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE,
Desjardins A, et al: Tetanus toxoid and CCL3 improve dendritic cell
vaccines in mice and glioblastoma patients. Nature. 519:366–369.
2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Berneman ZN, De Laere M, Germonpré P,
Huizing MT, Willemen Y, Lion E, De Reu H, Van den Bossche J, Van
den Brande J, Specenier P, et al: WT1-mRNA dendritic cell
vaccination of patients with glioblastoma multiforme, malignant
pleural mesothelioma, metastatic breast cancer, and other solid
tumors: Type 1 T-lymphocyte responses are associated with clinical
outcome. J Hematol Oncol. 18(9)2025.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Garfinkle EAR, Perales-Linares R, Gimple
RC, Livingstone AJ, Roberts KF, Butt OH, Goedegebuure SP, McLellan
MD, Chang GS, Hundal J, et al: Adjuvant personalized multivalent
neoantigen DNA vaccination for MGMT unmethylated glioblastoma: A
phase 1 trial. Nature Cancer. 7:1064–1079. 2026.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Van Den Bent MJ, French P, Eoli M,
Sepúlveda JM, Walenkamp AME, Frenel JS, Franceschi E, Clement PM,
Weller M, de Heer I, et al: Updated results of the INTELLANCE
2/EORTC trial 1410 randomized phase II study on Depatux-M alone,
Depatux-M in combination with temozolomide (TMZ) and either TMZ or
lomustine (LOM) in recurrent EGFR amplified glioblastoma
(NCT02343406). J Clin Oncol: Jun 1, 2018 (Epub ahead of print).
doi: 10.1200/JCO.2018.36.15_suppl.202.
|
|
37
|
Padovan M, Eoli M, Pellerino A, Rizzato S,
Caserta C, Simonelli M, Michiara M, Caccese M, Anghileri E,
Cerretti G, et al: Depatuxizumab mafodotin (Depatux-M) plus
temozolomide in recurrent glioblastoma patients: Real-world
experience from a multicenter study of italian association of
Neuro-oncology (AINO). Cancers (Basel). 13(2773)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mair MJ, Bartsch R, Le Rhun E, Berghoff
AS, Brastianos PK, Cortes J, Gan HK, Lin NU, Lassman AB, Wen PY, et
al: Understanding the activity of antibody-drug conjugates in
primary and secondary brain tumours. Nat Rev Clin Oncol.
20:372–389. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gan HK, van den Bent M, Lassman AB,
Reardon DA and Scott AM: Antibody-drug conjugates in glioblastoma
therapy: The right drugs to the right cells. Nat Rev Clin Oncol.
14:695–707. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Furnari FB, Cloughesy TF, Cavenee WK and
Mischel PS: Heterogeneity of epidermal growth factor receptor
signalling networks in glioblastoma. Nat Rev Cancer. 15:302–310.
2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Todo T, Ito H, Ino Y, Ohtsu H, Ota Y,
Shibahara J and Tanaka M: Intratumoral oncolytic herpes virus G47∆
for residual or recurrent glioblastoma: A phase 2 trial. Nat Med.
28:1630–1639. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Nassiri F, Patil V, Yefet LS, Singh O, Liu
J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, et al:
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent
glioblastoma: A phase 1/2 trial. Nat Med. 29:1370–1378.
2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Desjardins A, Gromeier M, Herndon JE II,
Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F,
Muscat AM, Nair S, et al: Recurrent Glioblastoma treated with
recombinant poliovirus. N Engl J Med. 379:150–161. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Suvà ML, Riggi N, Janiszewska M,
Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino
D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem
cell maintenance. Cancer Res. 69:9211–9218. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jin X, Kim LJY, Wu Q, Wallace LC, Prager
BC, Sanvoranart T, Gimple RC, Wang X, Mack SC, Miller TE, et al:
Targeting glioma stem cells through combined BMI1 and EZH2
inhibition. Nat Med. 23:1352–1361. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Stefan D, Lesueur P, Lequesne J, Feuvret
L, Bronnimann C, Castéra M, Brachet PE, Hrab I, Ducloie M, Lacroix
J, et al: Olaparib, temozolomide and concomitant radiotherapy for
partially or biopsy-only glioblastoma first-line treatment: Results
from the OLA-TMZ-RTE-01 phase 1 study. Clin Cancer Res.
31:1212–1222. 2025.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Natsume A, Ito M, Katsushima K, Ohka F,
Hatanaka A, Shinjo K, Sato S, Takahashi S, Ishikawa Y, Takeuchi I,
et al: Chromatin regulator PRC2 is a key regulator of epigenetic
plasticity in glioblastoma. Cancer Res. 73:4559–4570.
2013.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Minami JK, Morrow D, Bayley NA, Fernandez
EG, Salinas JJ, Tse C, Zhu H, Su B, Plawat R, Jones A, et al:
CDKN2A deletion remodels lipid metabolism to prime glioblastoma for
ferroptosis. Cancer Cell. 41:1048–1060.e9. 2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Duman C, Yaqubi K, Hoffmann A, Acikgöz AA,
Korshunov A, Bendszus M, Herold-Mende C, Liu HK and Alfonso J:
Acyl-CoA-binding protein drives glioblastoma tumorigenesis by
sustaining fatty acid oxidation. Cell Metab. 30:274–289.e5.
2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Masui K, Tanaka K, Akhavan D, Babic I,
Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, et al: mTOR
complex 2 controls glycolytic metabolism in glioblastoma through
FoxO acetylation and upregulation of c-Myc. Cell Metab. 18:726–739.
2013.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ye Z, Ai X, Yang K, Yang Z, Fei F, Liao X,
Qiu Z, Gimple RC, Yuan H, Huang H, et al: Targeting microglial
metabolic rewiring synergizes with immune-checkpoint blockade
therapy for glioblastoma. Cancer Discov. 13:974–1001.
2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Waibl Polania J, Hoyt-Miggelbrink A,
Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E,
Woroniecka K, Finlay JB, Ayasoufi K and Fecci PE: Antigen
presentation by tumor-associated macrophages drives T cells from a
progenitor exhaustion state to terminal exhaustion. Immunity.
58:232–246.e6. 2025.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang W, Li T, Cheng Y, Li F, Qi S, Mao M,
Wu J, Liu Q, Zhang X, Li X, et al: Identification of hypoxic
macrophages in glioblastoma with therapeutic potential for
vasculature normalization. Cancer Cell. 42:815–832.e12.
2024.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Sattiraju A, Kang S, Giotti B, Chen Z,
Marallano VJ, Brusco C, Ramakrishnan A, Shen L, Tsankov AM,
Hambardzumyan D, et al: Hypoxic niches attract and sequester
tumor-associated macrophages and cytotoxic T cells and reprogram
them for immunosuppression. Immunity. 56:1825–1843.e6.
2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Jeon HM, Kim JY, Cho HJ, Lee WJ, Nguyen D,
Kim SS, Oh YT, Kim HJ, Jung CW, Pinero G, et al: Tissue factor is a
critical regulator of radiation therapy-induced glioblastoma
remodeling. Cancer Cell. 41:1480–1497.e9. 2023.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Hoogstrate Y, Draaisma K, Ghisai SA, van
Hijfte L, Barin N, de Heer I, Coppieters W, van den Bosch TPP,
Bolleboom A, Gao Z, et al: Transcriptome analysis reveals tumor
microenvironment changes in glioblastoma. Cancer Cell.
41:678–692.e7. 2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Man J, Yu X, Huang H, Zhou W, Xiang C,
Huang H, Miele L, Liu Z, Bebek G, Bao S and Yu JS: Hypoxic
induction of vasorin regulates Notch1 turnover to maintain glioma
Stem-like cells. Cell Stem Cell. 22:104–118.e6. 2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Li Z, Bao S, Wu Q, Wang H, Eyler C,
Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al:
Hypoxia-inducible factors regulate tumorigenic capacity of glioma
stem cells. Cancer Cell. 15:501–513. 2009.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wu Y, Song Y, Wang R and Wang T: Molecular
mechanisms of tumor resistance to radiotherapy. Mol Cancer.
22(96)2023.PubMed/NCBI View Article : Google Scholar
|
